title: Progesterone receptor activity and relapse-free survival in patients with primary breast cancer: the role of adjuvant chemotherapy.
abstract: The prognostic significance of progesterone receptor activity (PgR) with regard to the estimated relapse-free survival (RFS) was studied in 350 one-center patients with primary breast cancer. All receptor assays were performed in one laboratory; PgR levels greater than 10 fmol/mg protein were considered positive. Univariate as well as multivariate statistical analyses were used to examine the prognostic significance of several variables. Eighty-nine of the 350 patients received adjuvant CMF chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil). The median observation period was 69 months (range 12-125 months). In the group of 261 patients who did not receive adjuvant CMF, the PgR-status lacked prognostic significance; only the lymph node status significantly affected the RFS (p less than 0.00001). In contrast, in the CMF-treated group of patients, the PgR-status was the most powerful predictor of recurrence (p less than 0.001). Premenopausal CMF-treated patients with PgR+ tumors had a significantly longer RFS than those with PgR- tumors (p less than 0.02). The present data urge the need for a reappraisal of the prognostic significance of PgR and of the mechanism of action of adjuvant chemotherapy in primary breast cancer.
authors: Department of Medicine, University Hospital Nijmegen, The Netherlands.
authors: J M
authors: JM
authors: Raemaekers
authors: L V
authors: LV
authors: Beex
authors: G F
authors: GF
authors: Pieters
authors: A G
authors: AG
authors: Smals
authors: T J
authors: TJ
authors: Benraad
authors: P W
authors: PW
authors: Kloppenborg
mesh_terms: D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000032:analysis* / Q000188:drug therapy / Q000401:mortality; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D011379:Prognosis; D011980:Receptors, Progesterone / Q000032:analysis*
chemical_list: D011980:Receptors, Progesterone; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate